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Abstract
The	pathophysiology	of	 chronic	nonbacterial	osteomyelitis	 (CNO)	 remains	 incompletely	understood.	 Increased	NLRP3	 inflammasome	activation	and	 IL-1β	 release	 in	monocytes	 from	CNO	patients	was	 suggested	 to
contribute	 to	 bone	 inflammation.	 Here,	 we	 dissect	 immune	 cell	 infiltrates	 and	 demonstrate	 the	 involvement	 of	 monocytes	 across	 disease	 stages.	 Differences	 in	 cell	 density	 and	 immune	 cell	 composition	 may	 help	 to
discriminate	between	BOM	and	CNO.	However,	differences	are	subtle	and	infiltrates	vary	in	CNO.	In	contrast	to	other	cells	involved,	monocytes	are	a	stable	element	during	all	stages	of	CNO,	which	makes	them	a	promising
candidate	in	the	search	for	“drivers”	of	inflammation.	Furthermore,	we	link	increased	expression	of	inflammasome	components	NLRP3	and	ASC	in	monocytes	with	site-specific	DNA	hypomethylation	around	the	corresponding
genes	NLRP3	and	PYCARD.	Our	observations	deliver	further	evidence	for	the	involvement	of	pro-inflammatory	monocytes	in	the	pathophysiology	of	CNO.	Cellular	and	molecular	alterations	may	serve	as	disease	biomarkers
and/or	therapeutic	targets.
1.1	Introduction
Chronic	nonbacterial	osteomyelitis	(CNO)	is	an	autoinflammatory	bone	disorder.	While	all	age	groups	can	be	affected,	peak	onset	ranges	between	7	and	12 years.	A	subset	of	CNO	patients	develops	inflammatory	lesions	in
single	 bones	 that	 can	 sometimes	be	 timely	 limited.	Most	 patients,	 however,	 experience	 chronic	 recurrent	 courses	with	more	 or	 less	 symmetric	 lesions	 at	multiple	 sites.	 Such	 courses	 are	 usually	 referred	 to	 as	 chronic	 recurrent
multifocal	osteomyelitis	(CRMO)	[1–3].	Particularly	cases	with	high	disease	activity,	and/or	delayed	diagnosis	and	treatment	initiation	are	prone	to	develop	additional	inflammatory	symptoms,	including	palmoplantar	pustulosis,	arthritis
or	bowel	inflammation.	Some	patients	experience	severe	sequelae,	such	as	vertebral	body	fractures.	Timely	diagnosis	and	initiation	of	effective	treatment	can	be	challenging	in	individual	cases	caused	by	the	absence	of	prospectively
tested	 disease	 biomarkers	 or	 diagnostic	 criteria	 [3,4].	 Thus,	CNO/CRMO	 remains	 a	 diagnosis	 of	 exclusion	 that	 requires	 the	 consideration	 of	 differential	 diagnoses,	 including	 infectious	 osteomyelitis,	malignancies	 and	 other	 rare
conditions	(such	as	the	metabolic	bone	disease	hypophosphatasia	and	other	autoinflammatory	conditions).	In	unclear	cases,	differential	diagnoses,	namely	bone	infection	or	malignancies,	require	to	be	excluded	through	bone	biopsies
[2,3,5].
To	date,	 the	exact	molecular	pathophysiology	of	CNO/CRMO	remains	unknown.	Descriptive	analyses	of	bone	biopsies	suggest	 the	presence	of	more	or	 less	distinct	disease	stages	 [2,6,7].	“Early	lesions”	 suggest	 a	 central
contribution	of	innate	immune	cells,	namely	neutrophils	and	monocytes,	in	disease	pathophysiology,	while	“later	stage”	bone	biopsies	are	characterized	by	infiltrates	of	lymphocytes	and	plasma	cells.	However,	based	on	the	rarity	of
CNO,	the	fact	that	only	a	relatively	small	subset	of	patients	requires	diagnostic	bone	biopsies,	and	lastly	and	most	importantly	the	fact	that	the	interval	between	disease-onset	and	bone	biopsy	remains	unclear	in	all	cases,	a	clear
definition	of	“early”	vs.	“late”	was	impossible,	and	lastly	based	on	the	visual	impression	in	histopathological	samples.	The	presence	of	innate	immune	cells	particularly	in	presumably	“early	lesions”,	contributed	to	the	conclusion,	that
CNO/CRMO	is	an	autoinflammatory	bone	disorder.	However,	the	contribution	of	adaptive	immune	cells	in	“late	phase”	bone	lesions	has	not	been	investigated	and	remains	elusive.
While	 the	exact	molecular	pathophysiology	of	CNO	 is	 incompletely	understood,	 recent	data	 suggest	 reduced	 IL-10	expression	and	uninhibited	NLRP3	 inflammasome	activation	 in	monocytes	 from	CNO	patients	 as	 central
contributors	to	bone	inflammation	and	resulting	clinical	symptoms	[8–10].	Scianaro	et	al.	(2014)	detected	increased	mRNA	expression	of	IL-1β	and	NLRP3	inflammasome	components	NLRP3	(NLRP3	gene),	ASC	(PYCARD	gene)	and
caspase-1	(CASP1	gene)	in	PBMCs	from	active	CRMO	patients	[11].	We	recently	demonstrated	increased	IL-1β	expression	and	release	in	monocytes	from	CRMO	patients	[8].	Furthermore,	we	and	others	identified	NLRP3	and	IL-1β
protein	in	inflamed	bone	regions	from	CRMO	patients	[8].	Whether	monocytes	or	other	immune	cells	(e.g.	neutrophils)	are	a	source	of	these	proteins	and	whether	individual	cells	produce	increased	amounts	of	NLRP3	inflammasome-
associated	mediators	remained	unclear.	Furthermore,	the	exact	molecular	mechanisms	that	contribute	to	increased	inflammasome	expression	and	resulting	IL-1β	activation	and	release	remained	unknown.
In	the	present	study,	we	aimed	to	investigate	immune	cell	infiltrates	in	bone	biopsies	from	CRMO	patients,	particularly	the	presence	of	monocytes	at	different	disease	stages,	to	assess	their	potential	contribution	to	both	early
phase	and	chronic	bone	inflammation.	Furthermore,	we	examined	the	expression	of	pro-inflammatory	IL-1β,	and	NLRP3	inflammasome-associated	genes	(NLRP3,	CASP1,	PYCARD)	in	monocytes	and	DNA	methylation	patterns	that	may
contribute	to	gene	dysregulation	in	CNO/CRMO	[8].
2.2	Materials	and	Mmethods
2.1.2.1	Patients	and	controls
All	patients	with	CNO/CRMO	or	bacterial	osteomyelitis	 (BOM)	included	 in	this	study	were	diagnosed	at	the	Department	of	Pediatrics,	Universitätsklinikum	Carl	Gustav	Carus,	TU	Dresden,	Dresden,	Germany	or	University
Children's	Hospital	Würzburg,	University	of	Würzburg,	Würzburg,	Germany.	Bone	tissue	was	collected	during	routine	diagnostic	workup	(CNO/CRMO	and	BOM)	or	during	elective	bone	osteotomy	procedures.	Lithium	heparin	blood
was	collected	from	treatment	naïve	CRMO	patients	and	healthy	controls	(patients	undergoing	elective	surgery)	for	the	isolation	of	monocytes.	The	use	of	tissue	from	routine	bone	biopsies,	immune	staining,	collection	of	blood	samples
and	immune	cell	isolation	and	use	was	permitted	by	local	ethics	committees.
2.2.2.2	Immunohistochemistry
Paraffin	embedded	bone	samples	from	4	CNO	patients,	3	patients	with	bacterial	osteomyelitis	(BOM)	as	disease	controls,	and	2	healthy	individuals	were	decalcified,	and	mounted	on	slides	in	preparation	for	antibody	staining.
Demographics	of	CNO/CRMO	patients,	bacterial	osteomyelitis	patients	and	controls	were	comparable.	None	of	the	patients	received	systemic	treatment	other	than	NSAID	at	the	time	of	surgery.
Slides	were	processed	using	the	Ventana	Benchmark	ultra-automated	system	with	proprietary	reagents	(Roche/Ventana	Medical	Systems).	Heat	induced	antigen	retrieval	method	was	used	in	Cell	Conditioning	solution	(CC1;
Roche/Ventana).	The	following	antibodies	were	used	for	immunostaining:	anti-CD14	(Ventana/Roche;	EPR	3653)	for	monocytes,	anti-CD15	(Cell	Marque;	MMA)	for	neutrophils,	anti-CD138	(Cell	Marque;	B-A38)	for	plasma	cells,	anti-
CD20	 (DAKO;	 L26)	 for	B	 lymphocytes,	 and	 anti-CD3	 (Ventana;	 2GV6)	 for	 T	 lymphocytes.	 Antibody	 detection	was	 performed	using	UltraView	universal	DAB	 and	UltraView	universal	 alkaline	 phosphatase	 red	 kit	 (Roche/Ventana).
Hematoxylin	II	and	bluing	reagent	(Ventana/Roche)	were	used	for	chromogenic	counterstaining	following	standard	protocols.	Cell	numbers	were	determined	in	4‐–10	visual	fields	(32,188.77 μm2)	per	individual	adding	up	to	36	in	CNO,
25	in	BOM,	and	12	in	the	control	group.	The	number	of	investigated	visual	fields	per	individual	depended	on	the	presence	and	size	of	bone	lesions	in	the	mounted	tissue	and	sample	quality.
2.3.2.3	Cell	isolation	and	culture
Peripheral	blood	mononuclear	cells	(PBMCs)	were	collected	by	density	gradient	centrifugation	(Lymphoprep,	Nycomed).	From	PBMCs,	CD14+	monocytes	were	isolated	by	negative	selection	(Stemcell	Technologies).	Monocytes
were	cultured	at	a	concentration	of	1x × 106 cells/mL	in	DMEM	with	10%	FCS.	Some	cells	were	treated	with	 lipopolysaccharide	(10 ng/mL)	 for	16 h.	Cells	were	harvested	 for	subsequent	qRT-PCR	and	DNA	methylation	analyses	as
indicated.
2.4.2.4	Real-time	PCR
Semiquantitative	real-time	PCR	(qRT-PCR)	was	performed	in	samples	from	6	CNO/CRMO	patients	and	6	controls,	using	GoTaq	qPCR	Master	Mix	Real	time	PCR	system	(ProMega)	according	to	manufacturer's	 instructions.
Results	were	normalized	to	GAPDH	and	a	calibrator	of	pooled	human	cDNA	derived	from	ex	vivo	isolated	“untouched”	CD14+	monocytes	(Stemcell	Technologies)	included	on	all	PCR	plates.	Real-time	PCR	data	were	analyzed	using	the
comparative	CT	method	[12].
2.5.2.5	Western	blotting
Resting	or	LPS	stimulated	(see	above)	CD14+	monocytes	(Stemcell	Technologies)	from	4	CNO/CRMO	patients	and	4	controls	were	lysed	and	processed	as	reported	previously	[13].	After	centrifugation	(16,400 g;	30 	minutesmin;
4 °C),	supernatants	were	collected	and	an	identical	amount	of	protein	from	each	lysate	(5 μg/well)	was	separated	on	NuPAGE	4%‐–12%	Bis-Tris	Gel	(Life	Technologies).	Proteins	were	transferred	to	a	nitrocellulose	membrane,	which	was
subsequently	blocked	for	1 	hourh	using	2%	BSA	in	PBS	and	incubated	at	room	temperature	with	anti-NLRP3	(AG-20B-0014,	AdipoGen),	anti-IL-1β	(sc-7884,	Santa	Cruz),	anti-ASC	(AL177,	AdipoGen),	anti-caspase-1	(sc-622,	Santa	Cruz),
and	anti-GAPDH	(H86504M-BU,	Meridian	Life	Science).	The	membrane	was	washed	with	TBS-T	and	incubated	with	a	1:3,000	dilution	of	secondary	antibody	(goat	anti-mouse	IgG	or	donkey	anti-rabbit	IgG)	coupled	with	HRP	(Jackson
Immunoresearch).	The	Imaging	System	c300	(Azure	Biosystems)	was	used	for	detection.
2.6.2.6	DNA	methylation	qPCR
Mouse	and	human	IL1B,	NLRP3,	and	PYCARD	genes	were	aligned,	and	conserved	non-coding	sequences	(CNS)	regions	were	determined	(VISTA	Genome	Browser).	CNS	regions	were	defined	as	regions	with	sequence	homology
of	over	75%	between	the	human	and	mouse	genes	over	at	least	200	base	pairs.	Based	on	the	degree	of	conservation,	distribution	of	CpG	sequences	and	the	presence	of	methylation-sensitive	restriction	sites	(MSRE	sites),	five	regions
of	interest	were	identified	across	the	genes	(Figure.	4A-C).	OneStep	qMethyl	kit	(Zymo	Research)	was	used	as	a	real-time	procedure	for	the	determination	of	DNA	methylation	of	specific	sequences	by	MSRE	digestion	and	quantitative
polymerase	chain	reaction	(PCR),	following	manufacturer's	instructions.	Human	genomic	DNA	derived	from	ex	vivo	isolated	“untouched”	CD14+	monocytes	from	6	CNO/CRMO	patients	and	6	controls	was	used	as	template.
2.7.2.7	Statistical	analysis
Statistical	analysis	was	performed	using	STATA	12.0	software	(StataCorp,	College	Station,	TX,	USA).	Non-parametric	tests	were	used	due	to	small	sample	size	and	skewness	of	our	data.	Differences	between	two	groups	were
analyzed	using	two-tailed	Wilcoxon	rank-sum	(Mann–Whitney)	tests	for	continuous	variables.	Kruskal-Wallis	test	was	used	to	evaluate	significance	between	independent	variables	of	three	groups.	For	all	analyses,	two-sided	p	values	of
<0.05	were	considered	statistically	significant.
3.3	Results
3.1.3.1	Immune	infiltrates	in	CNO/CRMO
The	composition	of	 immune	cell	 infiltrations	was	determined	 in	bone	biopsies	 from	CNO/CRMO	patients,	BOM	patients,	and	healthy	controls	 (children	undergoing	osteotomy)	 (Figure.	1).	 In	 line	with	 the	existing	 literature,
immune	cell	infiltrates	in	CNO/CRMO	patients	were	variable,	potentially	reflecting	different	disease	stages.	Based	on	immune	cell	infiltrates,	and	definitions	from	previous	reports,	we	divided	investigated	power	fields	(32,188.77 μm2
each)	in	three	groups	based	on	their	visual	appearance	in	hematoxylin	and	eosin	(HE)	stains:	i)	“early	phase	noninfectious	osteomyelitis”	with	mainly	segmented	nuclear	cells	(neutrophils)	and	large	mononuclear	(monocyte)	infiltrates,
ii)	“mixed	pattern”	infiltrates	with	small	mononuclear	blood	cells	(lymphocytes)	and	interspersed	conglomerates	of	neutrophils	and	monocytes,	and	iii)	“late	phase	noninfectious	osteomyelitis”	with	mostly	lymphocyte	infiltrates	(Figure.
1A).
Next,	we	performed	a	cell	count	in	all	included	power	fields,	and	determined	the	number	of	cells	and	the	proportion	of	monocytes	(CD14+),	neutrophils	(CD15+),	T	lymphocytes	(CD3+),	B	lymphocytes	(CD20+),	and	plasma	cells
(CD138+)	as	a	fraction	of	all	nucleated	cells	in	the	area	(Figures.	1,	2).	Significant	differences	in	absolute	numbers	of	monocytes	(p = 0.0001),	neutrophilic	granulocytes	(p = 0.0001),	T	lymphocytes	(p = 0.0001),	B	lymphocytes	(p < 0.002)
and	plasma	cell	(p = 0.0001)	have	been	detected	between	BOM,	CNO	and	healthy	controls	with	increased	counts	in	both	included	forms	of	osteomyelitis	(tableTable	1).
Figure	1Fig.	1	Morphological	appearance	of	bone	lesions	in	BOM	and	CNO/CRMO.	The	composition	of	immune	cell	infiltrations	was	determined	in	bone	biopsies	from	4	CNO/CRMO	patients,	3	BOM	patients,	and	2	healthy	controls.	CNO/CRMO	patients	exhibited	variable
appearances	of	immune	cell	infiltrates	based	on	HE,	and	immune	cell	surface	molecule	staining.		Based	on	the	visual	appearance	of	immune	infiltrates,	we	divided	included	visual	fields	in	three	groups:	“early”	phase	noninfectious	osteomyelitis	with	mainly	segmented	nuclear	cells
(neutrophils)	and	large	mononuclear	(monocyte)	infiltrates	(left	panel),	“mixed	pattern”	infiltrates	with	small	mononuclear	blood	cells	(lymphocytes)	and	interspersed	conglomerates	of	neutrophils	and	monocytes	(middle	panel),	and	“late”	phase	noninfectious	osteomyelitis	with
mostly	lymphocyte	infiltrates	(right	panel).
alt-text:	Fig.	1
Table	1	Quantification	of	tissue	immune	cells.
alt-text:	Table	1
Cell	type Absolute	numbers:	CNO	vs.	BOM	vs.	controls	(Figfigure.	2,	left	panel) Immune	cells	relative	to	nucleated	cells:	BOM	vs.	CNO	(Figfigure.	2,	right	panel)
monocytes	(CD14+) p < 0.001 p < 0.05
Figure	2Fig.	2	Quantification	on	immune	cell	distribution	in	BOM,	CNO/CRMO	and	controls.	Paraffin	embedded	bone	samples	from	4	CRMO	patients	(36	power	fields),	3	patients	with	bacterial	osteomyelitis	(25	power	fields)	as	disease	control,	and	2	healthy	individuals	(12	power
fields)	were	used	for	immune	cell	quantification	through	immune	histochemistry.	Absolute	numbers	(left	panel)	and	proportions	of	immune	cells	relative	to	all	nucleated	cells	in	the	power	field	(right	panel)	were	determined.	In	bacterial	(BOM)	and	chronic	nonbacterial	osteomyelitis
(CNO)	monocyte	(A),	neutrophil	(B),	T	cell	(C),	B	cell	(D),	and	plasma	cell	(E)	counts	were	increased	as	compared	to	controls.	Numbers	of	B	lymphocytes	were	only	significantly	increased	in	BOM	(D)	as	compared	to	healthy	bone,	while	numbers	were	not	significantly	increased	in	CNO
(*p <0 .05;	**p <0 .01,	***p <0 .001).
alt-text:	Fig.	2
neutrophils	(CD15+) p < 0.001 p < 0.02
T	lymphocytes	(CD3+) p < 0.001 ns
B	lymphocytes	(CD20+) p = 0.002 ns
plasma	cells	(CD138+) p < 0.001 p < 0.02
Kruskal-Wallis	tests	provide	one	p	value	representing	potential	differences	between	all	groups	included	in	statistical	analyses	(here:	3	groups	comparing	absolute	numbers	between	CNO,	BOM	and	controls).	Wilcoxon
rank-sum	(Mann-Whitney)	tests	were	used	comparing	relative	numbers	of	BOM	vs.	CNO	samples.	Two-sided	p	values	of	<0.05	were	considered	statistically	significant.
Morphological	descriptions	in	the	literature	suggest	that	early	stage	biopsies	of	CNO	patients	and	biopsies	from	BOM	patients	may	be	characterized	by	predominant	infiltrates	of	neutrophils	and	monocytes.	Thus,	we	used
morphological	appearance	in	HE	stains	to	divide	CNO	samples	in	three	groups	(“early”,	“mixed	pattern”,	and	“late”	stage	CNO)	(Figures.	1,	2,	Supplement	1).	Absolute	numbers	of	immune	cells	in	samples	from	CNO,	BOM	patients	and
controls	were	 compared	 and	 analyzed,	 applying	 Kruskal-Wallis	 tests.	 Significant	 differences	 between	 the	 three	 groups	were	 present	 in	 the	 numbers	 of	 all	 immune	 cell	 types	 investigated:	 CD14+	 monocytes,	 CD15+	 neutrophilic
granulocytes,	CD3+	T	lymphocytes,	CD20+	B	lymphocytes,	and	CD138+	plasma	cells	(Figure.	2,	 left	panel).	Next,	immune	cells	ratios	as	a	fraction	of	nucleated	cells	within	visual	fields	were	compared	between	BOM	and	CNO	using
Wilcoxon	rank-sum	(Mann–Whitney)	test	(Figure.	2,	righ	panel).	Normal	controls	were	excluded	from	data	sub-analysis,	since	low	total	cell	numbers	in	visual	fields	from	healthy	controls	may	have	resulted	in	datasets	of	limited	biological
relevance.	Relative	numbers	of	monocytes	(p < 0.05),	neutrophilic	granulozytes	(p < 0.02)	and	plasma	cells	(p < 0.02)	based	on	the	number	of	total	nucleated	cells	were	elevated	in	BOM	as	compared	to	CNO.	Lastly,	cell	numbers	and
proportions	in	bone	tissue	from	CNO	patients	with	“early”,	“mixed	pattern”	or	“late	stage”	bone	changes	were	compared	(Supplement	1).	Differences	in	absolute	cell	numbers	were	detected	in	monocytes	(p < 0.05)	and	B	lymphocytes
(p < 0.05),	which	were	elevated	in	“early”	CNO.	Neutrophilic	granulozyte	(p < 0.001),	T	cell	(p < 0.05),	and	B	lymphocyte	(p < 0.002)	proportions	relative	to	the	number	of	nucleated	cells	were	elevated	in	“early”	and	“mixed	pattern”
CNO	as	compared	to	“late”	stages.	Plasma	cells	trended	to	be	more	common	in	“late”	CNO	as	a	proportion	of	nucleated	cells.	This,	however,	failed	to	reach	statistical	significance.	As	mentioned	above,	absolute	and	relative	immune	cell
numbers	were	comparable	between	BOM	and	CNO	tissue.
Increased	 expression	 of	 NLRP3	 inflammasome-associated	 genes	 in	 CNO/CRMO	 ‐‐–	 Based	 on	 findings	 from	 previous	 reports	 and	 the	 observations	 in	 Figure.	 1,	 monocytes	 are	 likely	 to	 be	 central	 players	 in	 the	 immune
pathogenesis	of	CNO/CRMO.	To	assess	 their	potential	 contribution	 to	bone	 inflammation,	we	monitored	mRNA	 (Figure.	3A)	and	protein	 (Figure.	3B,	 Supplement	 2A)	 expression	 of	 IL-1,	NLRP3,	 caspase-1,	 and	ASC	 (PYCARD	 gene).
Expression	of	 IL-1β	was	 increased	 in	monocytes	 from	CNO/CRMO	patients	 under	 resting	 conditions	 and	 in	 response	 to	 stimulation	with	TLR4	 ligand	LPS	on	 the	mRNA	 level	 and	 increased	 on	 the	 protein	 level	 after	 stimulation.
Furthermore,	secretion	of	mature	IL-1β	was	increased	in	both	resting	and	stimulated	(LPS)	monocytes	from	CNO/CRMO	patients	when	compared	to	controls	(Supplement	2B).	Expression	of	NRLP3	mRNA	and	protein	was	increased	in
monocytes	 from	CNO/CRMO	patients	 in	response	 to	stimulation	when	compared	to	monocytes	 from	controls.	Other	 than	 in	a	previous	study	 that	 targeted	mRNA	expression	 in	PBMCs	 from	CNO/CRMO	patients,	caspase-1	mRNA
expression	was	comparable	in	monocytes	from	CRMO	patients	and	controls.	However,	there	was	a	trend	towards	increased	protein	expression	in	cells	from	CNO/CRMO	patients.	The	(mRNA)	expression	of	the	adapter	molecule	ASC
(PYCARD)	was	increased	in	monocytes	from	CRMO	patients	after	stimulation.
DNA	Methylation	patterns	in	monocytes	from	CNO/CRMO	patients	–	Previous	studies	suggested	altered	epigenetic	marks	to	contribute	to	altered	cytokine	expression	in	CNO	[8,10].	To	investigate	site-specific	DNA	methylation
patterns	across	the	(between	CNO	patients	and	controls)	differentially	expressed	human	IL1B,	NLRP3,	and	PYCARD	genes,	we	applied	bioinformatics	approaches	to	define	regions	of	interest	(ROI,	Figure.	4A-C).	Using	the	Vista	genome
browser	 inline	 tool	 (http://pipeline.lbl.gov/cgi-bin/gateway2),	 we	 aligned	mouse	 and	 human	 IL1B,	NLRP3,	 and	PYCARD	 genes	 to	 identify	 conserved	 non-coding	 sequences	 (CNS;	 pink),	 exons	 (blue)	 and	 untranslated	 regions	 (UTR;
turquoise).	Here,	CNS	sites	were	defined	as	regions	with	sequence	homology	of	>75%	between	human	and	mouse	over	a	length	of	at	least	200 bp.	CNS,	UTR	or	exons	were	defined	ROIs	when	CpG	sequences	(black	filled	circles	below
alignments	in	Figure.	4A-C)	were	present	and	DNA	sequences	included	methylation-sensitive	restriction	sites	(MSRE	sites)	that	allowed	the	chosen	PCR	based	analytic	approach	(OneStep	qMethyl	kit,	Zymo	Research).
Figure	3Fig.	3	Expression	of	NLRP3	inflammasome-associated	genes	in	monocytes	from	CNO/CRMO	patients.	A)	We	determined	mRNA	expression	of	IL-1β,	NLRP3,	caspase-1,	and	ASC	(encoded	by	PYCARD)	in	unstimulated	and	stimulated	(LPS)	monocytes	from	CRMO	patients	and
matched	controls.	Monocytes	from	CRMO	patients	express	increased	levels	of	IL-1β	as	compared	to	controls	under	resting	conditions	and	in	response	to	stimulation.	Furthermore,	expression	of	inflammasome	components	NLRP3	and	ASC	is	increased	in	monocytes	from	CRMO
patients	after	stimulation	with	LPS.	No	significant	differences	were	seen	in	caspase-1	expression.	B)	Protein	expression	was	monitored	in	monocytes	from	4	CRMO	patients	and	4	controls	(densitometry,	normalized	to	GAPDH	expression).	Samples	from	one	experiment	(including	one
CNO/CRMO	patient	and	one	matched	control),	are	connected	by	dotted	lines.	NLRP3	and	IL-1β	protein	expression	were	increased	in	monocytes	from	CRMO	patients	in	response	to	stimulation.	Furthermore,	we	determined	a	trend	towards	increased	expression	of	ASC	in	CRMO
monocytes	under	all	conditions,	and	a	trend	towards	increased	caspase-1	protein	expression	in	monocytes	from	CRMO	patients	in	cells	stimulated	with	LPS.
alt-text:	Fig.	3
While	no	significant	differences	were	determined	between	ROI1	and	2	of	the	IL1B	gene,	ROI1	of	NLRP3	and	ROI1	and	2	of	PYCARD	exhibited	significantly	reduced	DNA	methylation	levels	in	monocytes	from	CRMO	patients	as
Figure	4Fig.	4	DNA	methylation	of	NLRP3	inflammasome-associated	genes	in	monocytes	from	CRMO	patients.	Using	the	Vista	genome	browser	(http://pipeline.lbl.gov/cgi-bin/gateway2),	we	aligned	mouse	and	human	IL1B	(A),	NLRP3	(B),	and	PYCARD	(C)	genes	to	identify
conserved	non-coding	sequences	(CNS;	pink),	exons	(blue)	and	untranslated	regions	(UTR;	turquoise).	“High”	degrees	of	conservation	were	defined	by	sequence	homology	of	>75%	between	human	and	mouse	over	a	length	of	at	least	200 bp.	Regions	of	interest	(ROI)	were	defined	in
CNS,	UTR	or	exons	when	CpG	sequences	(black	filled	circles	below	alignments)	were	present	and	DNA	sequences	included	methylation-sensitive	restriction	sites	(MSRE	sites).	D)	DNA	methylation	patterns	varied	between	monocytes	from	CRMO	patients	(open	circles)	and	controls
(filled	circles).	ROI1	of	NLRP3	and	ROI1	and	2	of	PYCARD	exhibited	significantly	reduced	DNA	methylation	levels	in	monocytes	from	CRMO	patients	as	compared	to	cells	from	matched	healthy	controls.	No	differences	were	determined	between	ROI1	and	2	of	the	IL1B	gene.	(For
interpretation	of	the	references	to	colour	in	this	figure	legend,	the	reader	is	referred	to	the	web	version	of	this	article.)
alt-text:	Fig.	4
compared	to	cells	from	matched	healthy	controls	(Figure.	4D).
4.4	Discussion
Chronic	nonbacterial	osteomyelitis	has	been	classified	as	autoinflammatory	bone	disorder	because	of	the	involvement	of	spontaneous	activation	of	innate	immune	mechanisms	in	its	pathophysiology	[1,3,14,15].	A	central	step
on	the	way	was	the	descriptive	analysis	of	immune	cell	infiltrates	in	bone	biopsies	from	CNO/CRMO	patients.	To	date,	it	is	appreciated	that	immune	infiltrates	involve	innate	immune	cells,	particularly	during	“early”	disease	stages	that
are	replaced	or	complemented	by	lymphocytes	and	plasma	cells	in	“later”	disease	stages	[2,7].	However,	none	of	the	available	reports	provide	exact	quantification	of	immune	cells	and	mostly	rely	on	the	description	of	morphologic
features	in	HE	stains.	In	a	first	step,	we	quantified	immune	cells	in	bone	lesions	of	BOM	vs.	CNO/CRMO	patients	as	compared	to	healthy	bone	tissue.	Immune	cell	infiltrates	were	denser	in	BOM	as	compared	to	CNO/CRMO	with	higher
absolute	 and	 relative	numbers	 of	monocytes,	 neutrophils,	 T	 and	B	 lymphocytes.	 They	 furthermore,	 exhibited	 significant	 differences	 in	 immune	 cell	 numbers	 as	 compared	 to	 healthy	 controls	 (Table	1).	Next,	we	 for	 the	 first	 time
quantified	immune	cell	infiltrates	in	bone	biopsies	from	CNO/CRMO	patients	at	various	disease	stages	(“early”	vs.	“late”	stage)	and	compared	findings	to	bone	from	healthy	individuals	(osteotomy)	or	bacterial	osteomyelitis	(BOM).
Biopsies	 taken	at	any	stage	contained	monocytes,	neutrophils,	T	and	B	 lymphocytes,	and	plasma	cells.	However,	 “early”	 stage	 inflammation	was	characterized	by	 increased	absolute	numbers	of	monocytes,	 and	B	 lymphocytes	as
compared	to	later	stages.	Furthermore,	neutrophilic	granulozyte,	B	and	T	lymphocyte	proportions	were	elevated	in	“earlier”	stages	of	CNO	as	compared	to	chronic	stages.	Only	plasma	cells	appeared	to	increase	in	numbers	over	time
and	were	more	prevalent	in	“late	stage”-appearing	bone	lesions.	However,	since	plasma	cells	are	also	prevalent	in	bone	samples	from	BOM	patients,	the	sometimes-used	term	“plasma	cellular”	osteomyelitis	for	CNO/CRMO	appears
somewhat	misleading,	 since	 plasma	 cellular	 infiltrates	 are	 also	 present	 in	 BOM	 and	 therefore	 not	 specific	 to	 CNO/CRMO.	 Indeed,	 dense	 plasma	 cell	 infiltrates	 should	 trigger	 the	 consideration	 of	 differential	 diagnoses,	 such	 as
lymphoma.	Here	reported	observations	provide	evidence	for	a	coexistence	of	various	“disease	stages”	or	rather	mutual	involvement	of	innate	and	adaptive	immune	components	in	bone	inflammation	during	both	CNO/CRMO	and	BOM,
thus	underscoring	that	innate	and	adaptive	immune	responses	cannot	be	seen	as	individual	events.	Furthermore,	the	coexistence	of	innate	(monocytes	and	neutrophils)	and	adaptive	(lymphocyte)	immune	cell	infiltrates	in	CNO/CRMO
may	also	suggest	a	central	contribution	of	 innate	 immune	cells	 to	maintaining	 inflammation,	disease	 flares	or	phases	with	enhanced	disease	activity	 [16].	This	may	be	 in	analogy	to	Munro	micro-abscesses	 in	psoriasis,	a	disorder
associated	with	CNO/CRMO	that	may	also	share	molecular	pathomechanisms.	Munro	micro-abscesses	are	local	infiltrates	of	neutrophils	in	the	epidermis	of	psoriasis	patients	that	are	considered	to	promote	skin	inflammation	and/or
trigger	flares	in	plaque	psoriasis	[17,18].
The	constitutive	and	almost	unchanged	presence	of	monocytes	in	morphologically	diverse	infiltrates	in	CNO/CRMO	may	not	only	suggest	ongoing	interplay	between	components	of	the	innate	and	adaptive	immune	response,	but
also	suggests	a	central	contribution	of	monocytes	to	disease	pathology.	This	is	further	supported	by	the	previous	observation	that	monocytes	from	CRMO	patients	express	and	release	increased	amounts	of	pro-inflammatory	IL-1β	[8].
The	exact	molecular	mechanisms	that	contribute	to	 increased	gene	expression	and	activation,	however,	remained	unknown.	 In	the	present	study,	we	provide	evidence	for	 increased	mRNA	and	protein	expression	of	 inflammasome
associated	NLRP3,	ASC,	and	IL-1β.	Increased	abundance	of	inflammasome	components	NLRP3	and	ASC,	as	well	as	the	caspase-1	substrate	IL-1β	contribute	to	enhanced	inflammasome	assembly	and	subsequent	IL-1β	activation	and
release	 [19,20].	 Of	 note,	 intracellular	 protein	 levels	 of	 IL-1β	may	 even	 underestimate	 the	 total	 extend	 of	 IL-1β	 expression	 in	monocytes,	 since	 activated	mature	 IL-1β	 is	 secreted	 to	 the	 extracellular	 compartment,	 which	 is	 also
significantly	increased	in	monocytes	from	CNO/CRMO	patients	(as	seen	in	Supplement	1B).
Methylation	of	CpG	dinucleotides	within	DNA	sequences	resembles	a	potent	mechanism	to	prevent	recruitment	of	transcription	factors	and	RNA	polymerases	to	regulatory	regions	[21,22],	thereby	regulating	gene	expression.
In	previous	studies,	we	demonstrated	that	altered	epigenetic	marks	across	the	IL10	cytokine	gene	cluster	contribute	to	impaired	gene	expression	(8,	10).	Thus,	we	tested	whether	disturbed	epigenetic	patterns	may	also	contribute	to
increased	NLRP3	inflammasome	associated	gene	expression.	Indeed,	we	provide	evidence	suggesting	that	reduced	DNA	methylation	at	highly	conserved	elements	around	the	NLRP3	and	ASC	genes	 in	monocytes	 from	CNO/CRMO
patients	promote	gene	expression.	This	is	in	agreement	with	recent	data	from	Vento-Tormo	et	al.	(2017)	who	demonstrated	that	chronic	inflammasome	activation	in	a	group	of	genetic	inflammatory	disorders	referred	to	as	cryopyrin-
associated	 periodic	 syndromes	 (CAPS)	 is	 promoted	 by	 reduced	DNA	methylation,	 enhancing	 the	 transcription	 of	 inflammasome	 components	 [23].	 Indeed,	we	 detected	 increased	mRNA	 expression	 of	NLRP3	 and	 ASC/PYCARD	 in
monocytes	from	CNO/CRMO	patients	reflecting	reduced	DNA	methylation.	The	IL1B	gene,	which	is	transcriptionally	more	active	in	samples	from	CNO/CRMO	patients,	exhibited	comparable	DNA	methylation	patterns	between	both
groups	at	the	sites	investigated.	More	extensive	DNA	methylation	mapping,	including	more	distal	elements	may	provide	additional	information.	On	the	other	hand,	IL1B	may	be	more	resistant	to	changes	in	DNA	methylation	and	be
subject	to	dysregulation	through	additional	events	in	monocytes	from	CRMO	patients.
Currently,	 it	 remains	unknown	which	molecular	mechanisms	mediate	DNA	demethylation	at	 inflammasome-associated	genes	 in	monocytes	 from	CNO/CRMO	patients.	 It	 is	 tempting	 to	speculate	 that	 reduced	expression	of
immune	regulatory	cytokines	IL-10	and	IL-19	and	the	resulting	dysbalance	towardtowards	pro-inflammatory	cytokine	expression	in	monocytes	from	CNO/CRMO	patients	may	mediate	altered	DNA	methylation	[8].	However,	this	remains
to	be	determined	in	future	studies	and	is	beyond	the	scope	of	the	study	presented.	Another	possible	contributor	to	DNA	demethylation	is	the	reduced	activation	of	mitogen-activated	protein	kinases	(MAPKs)	ERK1	and	2	in	monocytes
from	CRMO	patients	[9,10].	Indeed,	T	cells	from	patients	with	the	autoimmune	disorder	systemic	lupus	erythematosus	undergo	DNA	demethylation	as	a	result	of	reduced	protein	kinase	activation	(involving	MAPK),	which	centrally
contributes	to	the	pro-inflammatory	effector	phenotype	of	these	cells	[24,25].
The	study	presented	is	limited	by	the	low	numbers	of	patients	and	controls,	which	was	caused	by	the	rarity	of	the	included	diagnoses	BOM	and	CNO,	the	fact	that	most	patients	with	these	diagnoses	do	not	undergo	routine
bone	biopsies,	 and	difficulties	 identifying	otherwise	healthy	 individuals	 requiring	osteotomy	surgery	 (of	note,	 osteopenic	 individuals	were	excluded).	Future	 studies	are	warranted	 to	 confirm	observations	 in	 larger	 cohorts	and	 to
address	open	questions	of	whether	reduced	expression	of	immune	regulatory	cytokines,	increased	expression	of	pro-inflammatory	cytokines,	other	mechanisms	such	as	altered	MAPK	activation,	or	a	combination	of	the	aforementioned
contribute	to	DNA	demethylation	in	monocytes	from	CRMO	patients.	For	these	investigations,	international	collaborations	are	required	to	allow	the	inclusion	of	larger	cohorts	with	sufficient	numbers	of	patients	at	different	disease
stages	and	with	differential	disease	presentation.	The	recently	published	CARRA	consensus	treatment	plan	(CTP)	initiative	aiming	at	treatment	harmonization	and	the	comparison	of	available	treatment	options	includes	the	collection	of
clinical	datasets	and	biosamples	[26].	Thus,	it	is	a	unique	opportunity	for	international	collaborations	targeting	the	molecular	pathophysiology	of	CNO/CRMO.
5.5	Conclusions
Cellular	infiltrates	in	bacterial	(BOM)	and	noninfectious	CNO/CRMO	include	innate	immune	cells	(neutrophils	and	monocytes)	and	lymphocytes.	Generally,	immune	cell	infiltrates	are	denser	in	BOM	as	compared	to	CNO/CRMO
potentially	reflecting	higher	inflammatory	activity	that	may	explain	more	acute	onset	of	symptoms.	In	BOM	and	in	“later	stage”	CNO	lesions,	plasma	cells	are	present.	Thus,	discrimination	between	BOM	and	CNO	solely	based	on
histopathology	 remains	difficult	using	currently	available	 tools.	Monocytes	are	prominent	 cellular	 components	of	 inflammatory	 infiltrates	 in	CNO/CRMO	at	all	 stages,	which	makes	 them	a	 likely	 contributor	 to	bone	 inflammation.
Monocytes	from	CRMO	patients	express	increased	levels	of	NLRP3	inflammasome	components	NLRP3	and	ASC,	as	well	as	IL-1β.	Altered	gene	expression	is	promoted	by	site-specific	DNA	demethylation	at	the	corresponding	genes
NLRP3	and	PYCARD	(ASC).	Taken	together,	reported	observations	provide	evidence	for	the	 involvement	of	monocytes	 in	the	 immune	pathogenesis	of	CNO	and	provide	additional	arguments	 for	cytokine	blocking	strategies	and/or
inflammasome	inhibition	in	CNO/CRMO	refractory	to	standard	treatment	with	NSAIDs.
Supplementary	data	to	this	article	can	be	found	online	at	https://doi.org/10.1016/j.clim.2018.04.011.
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Morphological	descriptions	in	the	literature	suggest	that	early	stage	biopsies	of	CNO	patients	and	biopsies	from	BOM	patients	may	be	characterized	by	predominant	infiltrates	of	neutrophils	and	monocytes.
Thus,	we	used	morphological	appearance	in	HE	stains	to	divide	CNO	samples	in	three	groups	(“early”,	“mixed	pattern”,	and	“late”	stage	CNO)	(Figures.	1,	2,	Supplement	1).	Absolute	numbers	of	immune	cells	in	samples
from	CNO,	BOM	patients	and	controls	were	compared	and	analyzed,	applying	Kruskal-Wallis	tests.	Significant	differences	between	the	three	groups	were	present	in	the	numbers	of	all	immune	cell	types	investigated:
CD14+	monocytes,	CD15+	neutrophilic	granulocytes,	CD3+	T	lymphocytes,	CD20+	B	lymphocytes,	and	CD138+	plasma	cells	(Figure.	2,	left	panel).	Next,	immune	cells	ratios	as	a	fraction	of	nucleated	cells	within	visual
fields	were	compared	between	BOM	and	CNO	using	Wilcoxon	rank-sum	(Mann–Whitney)	test	(Figure.	2,	righ	panel).	Normal	controls	were	excluded	from	data	sub-analysis,	since	low	total	cell	numbers	in	visual	fields
from	healthy	controls	may	have	resulted	in	datasets	of	limited	biological	relevance.	Relative	numbers	of	monocytes	(p < 0.05),	neutrophilic	granulozytes	(p < 0.02)	and	plasma	cells	(p < 0.02)	based	on	the	number	of
total	nucleated	cells	were	elevated	in	BOM	as	compared	to	CNO.	Lastly,	cell	numbers	and	proportions	in	bone	tissue	from	CNO	patients	with	“early”,	“mixed	pattern”	or	“late	stage”	bone	changes	were	compared
(Supplement	1).	Differences	in	absolute	cell	numbers	were	detected	in	monocytes	(p < 0.05)	and	B	lymphocytes	(p < 0.05),	which	were	elevated	in	“early”	CNO.	Neutrophilic	granulozyte	(p < 0.001),	T	cell	(p < 0.05),
and	B	lymphocyte	(p < 0.002)	proportions	relative	to	the	number	of	nucleated	cells	were	elevated	in	“early”	and	“mixed	pattern”	CNO	as	compared	to	“late”	stages.	Plasma	cells	trended	to	be	more	common	in	“late”
CNO	as	a	proportion	of	nucleated	cells.	This,	however,	failed	to	reach	statistical	significance.	As	mentioned	above,	absolute	and	relative	immune	cell	numbers	were	comparable	between	BOM	and	CNO	tissue.
Increased	expression	of	NLRP3	inflammasome-associated	genes	in	CNO/CRMO	‐‐–	Based	on	findings	from	previous	reports	and	the	observations	in	Figure.	1,	monocytes	are	likely	to	be	central	players	in	the
immune	pathogenesis	of	CNO/CRMO.	To	assess	their	potential	contribution	to	bone	inflammation,	we	monitored	mRNA	(Figure.	3A)	and	protein	(Figure.	3B,	Supplement	2A)	expression	of	IL-1,	NLRP3,	caspase-1,	and
ASC	(PYCARD	gene).	Expression	of	IL-1β	was	increased	in	monocytes	from	CNO/CRMO	patients	under	resting	conditions	and	in	response	to	stimulation	with	TLR4	ligand	LPS	on	the	mRNA	level	and	increased	on	the
protein	level	after	stimulation.	Furthermore,	secretion	of	mature	IL-1β	was	increased	in	both	resting	and	stimulated	(LPS)	monocytes	from	CNO/CRMO	patients	when	compared	to	controls	(Supplement	2B).	Expression
of	NRLP3	mRNA	and	protein	was	 increased	 in	monocytes	 from	CNO/CRMO	patients	 in	 response	 to	 stimulation	when	 compared	 to	monocytes	 from	controls.	Other	 than	 in	 a	previous	 study	 that	 targeted	mRNA
expression	in	PBMCs	from	CNO/CRMO	patients,	caspase-1	mRNA	expression	was	comparable	in	monocytes	from	CRMO	patients	and	controls.	However,	there	was	a	trend	towards	increased	protein	expression	in	cells
from	CNO/CRMO	patients.	The	(mRNA)	expression	of	the	adapter	molecule	ASC	(PYCARD)	was	increased	in	monocytes	from	CRMO	patients	after	stimulation.
The	constitutive	and	almost	unchanged	presence	of	monocytes	in	morphologically	diverse	infiltrates	in	CNO/CRMO	may	not	only	suggest	ongoing	interplay	between	components	of	the	innate	and	adaptive
immune	response,	but	also	suggests	a	central	contribution	of	monocytes	to	disease	pathology.	This	is	further	supported	by	the	previous	observation	that	monocytes	from	CRMO	patients	express	and	release	increased
amounts	of	pro-inflammatory	 IL-1β	 [8].	 The	 exact	molecular	mechanisms	 that	 contribute	 to	 increased	gene	expression	 and	activation,	 however,	 remained	unknown.	 In	 the	present	 study,	we	provide	 evidence	 for
increased	mRNA	and	protein	expression	of	inflammasome	associated	NLRP3,	ASC,	and	IL-1β.	Increased	abundance	of	inflammasome	components	NLRP3	and	ASC,	as	well	as	the	caspase-1	substrate	IL-1β	contribute
to	enhanced	inflammasome	assembly	and	subsequent	IL-1β	activation	and	release	[19,20].	Of	note,	intracellular	protein	levels	of	IL-1β	may	even	underestimate	the	total	extend	of	IL-1β	expression	in	monocytes,	since
activated	mature	IL-1β	is	secreted	to	the	extracellular	compartment,	which	is	also	significantly	increased	in	monocytes	from	CNO/CRMO	patients	(as	seen	in	Supplement	1B).
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The	following	are	the	supplementary	data	related	to	this	article.
Multimedia	Component	1
Supplement	1	Quantification	on	immune	cell	distribution	in	“early”,	“mixed	pattern”	and	“late”	CNO/CRMO.	Paraffin	embedded	bone	samples	from	4	CRMO	patients	(36	power	fields),	3	patients	with	bacterial	osteomyelitis	(25	power	fields)	as	disease
control,	and	2	healthy	individuals	(12	power	fields)	were	used	for	immune	cell	quantification	through	immune	histochemistry.	Absolute	numbers	(left	panel)	and	proportions	of	immune	cells	relative	to	all	nucleated	cells	in	the	power	field	(right	panel)	were
determined.	Differences	in	absolute	numbers	of	immune	cells	between	the	three	groups	of	CNO	samples	(“early”	CNO	(eCNO);	“mixed	pattern”	CNO	(mCNO);	“late	stage”	CNO	(lCNO))	were	detected	in	monocytes	and	B	cells.	Neutrophilic	granulocyte	and
B	cell	proportions	relative	to	the	number	of	nucleated	cells	were	elevated	in	“earlier”	stages	of	CNO	as	compared	to	“late”	stages.	Plasma	cells	 trended	to	be	more	common	in	“later”	CNO	stages.	This,	however,	 failed	to	reach	statistical	significance
(*p < 0.05;	**p < 0.01,	***p < 0.001).
alt-text:	Supplement	1
Multimedia	Component	2
Supplement	2	Expression	of	NLRP3	inflammasome-associated	genes	 in	monocytes	 from	CNO/CRMO	patients.	A)	Protein	expression	was	monitored	 in	monocytes	 from	4	CRMO	patients	and	4	controls.	One	representative	Western	blot	 is	provided.	B)
Secretion	of	mature	IL-1β	protein	from	monocytes	from	CNO/CRMO	patients	and	controls	under	resting	conditions	and	in	response	to	stimulation	with	LPS.	In	the	upper	panel,	absolute	values	of	IL-1β	protein	in	the	supernatant	are	displayed;	the	lower
panel	indicates	fold	increase	of	IL-1β	protein	secretion	from	monocytes	based	on	unstimulated	cells	from	healthy	controls	in	each	experiment.	Median	values,	standard	deviations,	and	p	values	from	Mann-Whitney	tests	are	provided.
alt-text:	Supplement	2
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• Immune	infiltrates	in	CNO	involve	cells	of	the	innate	and	adaptive	immune	system.
• Innate	immune	cells	may	drive	flares	in	analogy	to	Munro	abscesses	in	psoriasis.
• Monocytes	are	a	stable	and	almost	unchanged	element	of	all	CNO/CRMO	stages.
• Monocytes	from	CNO	patients	over-express	NLRP3,	ASC,	and	IL-1β
• Gene	expression	is	promoted	by	DNA	hypomethylation	at	NLRP3	and	PYCARD.
